Experiences of the combined use of Favipiravir in patients using Lorlatinib and Brigatinib

Abstract

Introduction The SARS-COV-2 (COVID-19) pandemic is challenging the management of cancer patients. In this article, we present two patients diagnosed with anaplastic lymphoma kinase (ALK) + non-small cell lung adenocarcinoma (NSCL CA), infected with COVID-19, who had a previous multi-line therapy with Brigatinib and Lorlatinib, and received Favipiravir for their current infection. Case reports A 58-year-old man and a 65-year-old woman were diagnosed as ALK ( + ) NSCL CA. Both patients received tyrosine kinase inhibitors (TKI) for lung cancer when diagnosed with COVID-19. No adverse effects were observed with the concurrent use of Favipiravir, an antiviral drug currently used for COVID-19 and TKI. Management and outcome Considering the pharmacokinetic effects of favipiravir and the ALK inhibitor TKI's used on our cases (Brigatinib-Lorlatinib), the concurrent use of these drugs was safe and prevented the delay in the primary treatment of the malignancy of our patients. Discussion To our knowledge, these are the only reported cases diagnosed as ALK ( + ) NSCL CA who received favipiravir because of COVID-19 while using TKI, and both patients recovered completely without any side effects.

Predictive importance of systemic inflammation response index in de novo brain metastatic small cell lung cancer patients

“…Treatment delays incancer patients can increase mortality. 14 For predicting the prognosis of SCLC, various factors have been investigated, but the lack of a standardized marker highlights the need for new biomarkers in this regard. 15 Inflamation markes are practical in many solid tumors.…”

Chemotherapy Timing During Visceral Crisis in Patients with Liver Metastatic Solid Carcinoma

“…[9] Delays in treatment can increase mortality in cancer patients. [10] Therefore, the early identification of factors influencing survival, the initiation of treatment with optimal timing, or early interventions for treatment in cancer-related hepatic dysfunction patients, especially in cases where survival is measured in mere weeks, can extend survival periods. The gold standard for assessing liver damage is liver biopsy.…”